Business ❯ Healthcare ❯ Pharmaceuticals

Vaccine Development

Bavarian Nordic Moderna Moderna Inc. Clinical Trials Acquisitions Next-Generation Medications mRNA Technology Licensing Agreements Infectious Diseases Strategic Partnerships Pricing Strategies Biontech Acquisition Smallpox Vaccine Funding Strategies CureVac Bavarian Nordic Vaccines Norovirus Vaccine Gardasil Patent Rights Public Health Public Health Policy AstraZeneca Respiratory Vaccines

Lilly Agrees to Buy Three Vaccine Developers for Up to $3.8 Billion

The purchases mark a strategic shift into vaccine-led prevention that Lilly says will move forward only after routine regulatory clearances.

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

Sanofi to Buy Dynavax for $2.2 Billion in All-Cash Tender Offer

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

Moderna Cuts 10% of Global Workforce in Major Cost Overhaul

Sanofi Signs $1.15 Billion Deal to Acquire Vicebio’s Molecular Clamp Respiratory Vaccine Platform